203 related articles for article (PubMed ID: 33587391)
1. Case Report: Valbenazine as a Treatment for Tardive Dyskinesia and Unexpected Antipsychotic Effects.
Khurram SK; Ames M; Muniz J
J Clin Psychopharmacol; 2021 Mar-Apr 01; 41(2):220-221. PubMed ID: 33587391
[No Abstract] [Full Text] [Related]
2. Valbenazine as the first and only approved treatment for adults with tardive dyskinesia.
Sarva H; Henchcliffe C
Expert Rev Clin Pharmacol; 2018 Mar; 11(3):209-217. PubMed ID: 29338466
[TBL] [Abstract][Full Text] [Related]
3. Valbenazine Treatment of Tardive Dyskinesia and of Positive Symptoms.
Lindenmayer JP; Burke E; Tsuboyama G; Chahal Y; Grewal HK
J Clin Psychopharmacol; 2022 Jan-Feb 01; 42(1):109-111. PubMed ID: 34668876
[No Abstract] [Full Text] [Related]
4. Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.
Caroff SN; Aggarwal S; Yonan C
J Comp Eff Res; 2018 Feb; 7(2):135-148. PubMed ID: 28965423
[TBL] [Abstract][Full Text] [Related]
5. Valbenazine (Ingrezza) for tardive dyskinesia.
Med Lett Drugs Ther; 2017 May; 59(1521):83-84. PubMed ID: 28520698
[No Abstract] [Full Text] [Related]
6. A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia.
Marder SR; Singer C; Lindenmayer JP; Tanner CM; Comella CL; Verghese C; Jimenez R; Liang GS; Burke J; OʼBrien CF
J Clin Psychopharmacol; 2019; 39(6):620-627. PubMed ID: 31688452
[TBL] [Abstract][Full Text] [Related]
7. Valbenazine-induced parkinsonism.
Akbar U; Kim DS; Friedman JH
Parkinsonism Relat Disord; 2020 Jan; 70():13-14. PubMed ID: 31785443
[No Abstract] [Full Text] [Related]
8. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
[TBL] [Abstract][Full Text] [Related]
9. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
Hauser RA; Factor SA; Marder SR; Knesevich MA; Ramirez PM; Jimenez R; Burke J; Liang GS; O'Brien CF
Am J Psychiatry; 2017 May; 174(5):476-484. PubMed ID: 28320223
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
Josiassen RC; Kane JM; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):61-68. PubMed ID: 28839341
[TBL] [Abstract][Full Text] [Related]
12. Valbenazine for the treatment of tardive dyskinesia.
Müller T
Expert Rev Neurother; 2017 Dec; 17(12):1135-1144. PubMed ID: 28971695
[TBL] [Abstract][Full Text] [Related]
13. Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia.
Khorassani F; Luther K; Talreja O
Am J Health Syst Pharm; 2020 Jan; 77(3):167-174. PubMed ID: 31974564
[TBL] [Abstract][Full Text] [Related]
14. Sustained Treatment Response and Global Improvements With Long-term Valbenazine in Patients With Tardive Dyskinesia.
Correll CU; Citrome L; Singer C; Lindenmayer JP; Zinger C; Liang G; Dunayevich E; Marder SR
J Clin Psychopharmacol; 2024 Jul-Aug 01; 44(4):353-361. PubMed ID: 38767901
[TBL] [Abstract][Full Text] [Related]
15. The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder.
McIntyre RS; Calabrese JR; Nierenberg AA; Farahmand K; Yonan C; Siegert S; Burke J
J Affect Disord; 2019 Mar; 246():217-223. PubMed ID: 30583148
[TBL] [Abstract][Full Text] [Related]
16. Revisiting Tardive Dyskinesia: Focusing on the Basics of Identification and Treatment.
Citrome L; Saklad SR
J Clin Psychiatry; 2020 Feb; 81(2):. PubMed ID: 32078259
[TBL] [Abstract][Full Text] [Related]
17. Early Recognition and Treatment of Tardive Dyskinesia in Patients With Mood Disorders and Schizophrenia.
McEvoy JP; Kremens DE
J Clin Psychiatry; 2020 Jan; 81(1):. PubMed ID: 31995674
[TBL] [Abstract][Full Text] [Related]
18. Valbenazine granted breakthrough drug status for treating tardive dyskinesia.
Müller T
Expert Opin Investig Drugs; 2015 Jun; 24(6):737-42. PubMed ID: 25809133
[TBL] [Abstract][Full Text] [Related]
19. Valbenazine in the treatment of tardive dyskinesia.
Witek N; Comella C
Neurodegener Dis Manag; 2019 Apr; 9(2):73-81. PubMed ID: 30724115
[TBL] [Abstract][Full Text] [Related]
20. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials.
Solmi M; Pigato G; Kane JM; Correll CU
Drug Des Devel Ther; 2018; 12():1215-1238. PubMed ID: 29795977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
